Sotirios Charalampos Diamantoudis^1,#,*, Androulla N. Miliotou^2,#, Eleftheria Galatou², Stergiani Telliou³, Konstantinos Sideris⁴, Nikolaos Grigoriadis¹, Ioannis S. Vizirianakis^1,2,*

BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216 - 22 October 2025

Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More > Graphic Abstract

GIOVANA GOMES CHAGAS¹, RUAN PIMENTA², NAYARA IZABEL VIANA^1,*

Oncology Research, Vol.33, No.6, pp. 1283-1288, 2025, DOI:10.32604/or.2025.055100 - 29 May 2025

Abstract The monoclonal antibodies consist of an innovative form of immunotherapy, capable of defeating several diseases, such as cancer. It is an emergent and important theme, that advances evaluation, challenges, and future perspectives with high relevance to identify gaps in recent studies and to consolidate this general theme in only one research. Its action in Chronic and Acute Lymphoid Leukemia has been evaluated in several clinical trials, which were selected between 2022 and 2023, in order to understand better the monoclonal antibodies that were most studied. The biopharmaceutical compounds Ibrutinib, Obinutuzumab, Rituximab, Venetoclax, and Inotuzumab Ozogamicin… More >

VERA RUZANOVA¹, ANASTASIA PROSKURINA¹, GENRIKH RITTER¹, EVGENIYA DOLGOVA¹, SOFYA OSHIKHMINA^1,2, SVETLANA KIRIKOVICH¹, EVGENIY LEVITES¹, YAROSLAV EFREMOV^2,3, OLEG TARANOV⁴, ALEXANDR OSTANIN⁵, ELENA CHERNYKH⁵, NIKOLAY KOLCHANOV⁶, SERGEY BOGACHEV^1,*

Oncology Research, Vol.33, No.5, pp. 1229-1248, 2025, DOI:10.32604/or.2025.059411 - 18 April 2025

Abstract Objectives: Currently, there exist two approaches to the treatment of malignant neoplasms: the Karanahan technology and in situ vaccination, which are based on chronometric delivery of therapeutic agents to the tumor depending on the characteristics of tumor cells, as well as the immune status. The main purpose of this study was to experimentally prove the feasibility of combining the Karanahan technology and in situ vaccination with αOX40 antibodies into a single therapeutic platform to achieve a potent additive antitumor therapeutic effect. Methods: BALB/c mice grafted with B-cellular lymphoma A20 were treated using the Karanahan technology consisting of… More >

Jo Van Damme^1,$, Ghislain Opdenakker^2,$, Sam Van Damme³, Soffe Struyf¹

European Cytokine Network, Vol.34, No.1, pp. 1-9, 2023, DOI:10.1684/ecn.2023.0484

Abstract Polyclonal antisera from patients have been at the basis of the description of autoimmune diseases and today monoclonal antibodies are widely used in the therapy of cancer and many inflammatory diseases. How antisera and antibodies in combination with traditional in vitro and in vivo biological test systems have been instrumental reagents for the discovery of new cytokines is illustrated here for interleukin-1, -6 and -8. Furthermore, widely used immunological detection/quantification systems, such as ELISAs and multiplex assays, based on the use of either polyclonal or monoclonal antibodies, are often fraught with misinterpretations, because the results are affected More >

FENG ZHU^*, QINQIN ZHANG, YANGKAI ZHOU, QIPING ZHANG, MENGYAO CAO, ZHAOLIN JI

BIOCELL, Vol.46, No.9, pp. 2123-2131, 2022, DOI:10.32604/biocell.2022.020229 - 18 May 2022

Abstract The NAC (NAM, ATAF, and CUC) superfamily is one of the largest plant-specific families containing transcription factors. An increasing number of studies suggest that NAC1 is involved in plants response to different biotic and abiotic stimulis. Nicotiana benthamiana is a widely used system for evaluating plant-pathogen interactions. In order to study the biochemical function of NbNAC1, NbNAC1 protein and antibody are essential. Therefore, we focused on developing a prokaryotic expression system for producing the Nicotiana benthamiana NbNAC1 protein of in Escherichia coli and the preparation of its polyclonal antibody. Firstly, we constructed two different molecular weight prokaryotic expression More >

VERA KOLYOVSKA^1,#, SONYA IVANOVA², DESISLAVA DRENSKA³, DIMITAR MASLAROV^3,4,#, RENETA TOSHKOVA^1,*

BIOCELL, Vol.45, No.6, pp. 1485-1494, 2021, DOI:10.32604/biocell.2021.016250 - 01 September 2021

Abstract Glycosphingolipids (gangliosides) have been characterized as important biological molecules with a key role as regulators in many physiological processes on cellular, tissue, organ, and organism levels. The deviations in their normal amounts, production, and metabolism are very often related to the development of many multi-factor socially important diseases. GM3 ganglioside, as a small molecule, plays important roles in the cascade regulatory pathways in the pathology of many disorders like neurodegenerative diseases, autoimmune diseases, inflammation, diabetes, malignant transformation, and others. Ganglioside GM3 and its derivatives are membrane-bound glycosphingolipids composed of an oligosaccharide head structure containing one… More >

Patrick D. Evers^1,*, Tarek Alsaied^1,2,*, Jeffrey B. Anderson¹, James F. Cnota¹, Allison A. Divanovic¹

Congenital Heart Disease, Vol.14, No.2, pp. 221-229, 2019, DOI:10.1111/chd.12713

Abstract Objective: Maternal anti-Ro/SSA and anti-La/SSB antibodies can lead to fetal complete heart block (CHB). Current guidelines recommend weekly echocardiographic screening between 16 and 28 weeks gestation. Given the cost of screening and the rarity of conduction abnormalities in fetuses of mothers with low anti-Ro levels (<50 U/mL), we sought to identify a strategy that optimizes resource utilization.
Design: Decision analysis cost-utility modeling was performed for three screening paradigms: “standard screening” (SS) in which mid-gestation mothers are screened weekly, “limited screening” (LS) in which fetal echocardiograms are avoided unless the fetus develops bradycardia, and “targeted screening by maternal… More >

Karinna Chouman¹, Birgit Korioth-Schmitz¹, Markus Sack², Jörn Engelbert Schmitz¹, Anh Tuan Pham¹, Rainer Fischer^2,4, Stefan Barth⁵, Torsten Klockenbring¹, Rolf Fendel^1,6

European Cytokine Network, Vol.29, No.2, pp. 59-72, 2018, DOI:10.1684/ecn.2018.0409

Abstract Interleukin-6 (IL-6) expression and secretion, induced by inflammatory processes, stimulate the acute phase response cascade. The overexpression of IL-6 contributes to a variety of inflammatory diseases, e.g. rheumatoid arthritis, Castleman’s disease, multiple myeloma, and prostate cancer. Screening for high amounts of IL-6 in the patients’ blood serum can be crucial for an adequate treatment. In this study, five novel murine monoclonal antibodies (mAbs) reactive to human IL-6 were generated. The mAbs were characterized for potential diagnostic purposes and recombinant antibodies were derived thereof. Initial epitope mapping using a combination of blocking experiments and Hyper-IL-6, a fusion… More >

José L. Aparicio¹, Macarena Ottobre¹, Maite Duhalde Vega¹, Jean-Paul Coutelier², Jacques Van Snick³, Lilia A. Retegui¹

European Cytokine Network, Vol.28, No.3, pp. 111-119, 2017, DOI:10.1684/ecn.2017.0399

Abstract Mice infected with mouse hepatitis virus A59 (MHV-A59) develop hepatitis and autoantibodies (autoAb) to liver and kidney fumarylacetoacetate hydrolase (FAH), a fact closely related to the release of alarmins such as uric acid and/or high-mobility group box protein 1 (HMGB1). We studied the effect of neutralizing monoclonal antibodies (MAb) against IL-17A in our model of mouseMHV-A59-infection.MAb anti-IL-17F and anti-IFNγ were used to complement the study. Results showed that transaminase levels markedly decreased in MHV-A59- infected mice treated with MAb anti-IL-17A whereas plasmatic Ig concentration sharply increased. Conversely, MAb anti-IL-17F enhanced transaminase liberation and did not More >

Jiro Hirota¹, Shinya Shimizu¹, Atsushi Watanabe², Fumiko Suzuta³, Kazue Yajima⁴, Kumiko Kimura⁵, Makoto Haritani⁵, Shigeki Inumaru¹, Yukio Yagi⁶

European Cytokine Network, Vol.22, No.1, pp. 73-80, 2011, DOI:10.1684/ecn.2011.0275

Abstract Three IgG class anti-bovine CXCL8 (bCXCL8) monoclonal antibody (mAb)-secreting hybridomas, SH8-8D7, SH8-12A5 and SH8-2A1, were developed. SH8-8D7 was IgG2a, and SH8-12A5 and SH8-2A1 were IgG1. All three mAbs detected recombinant bCXCL8 (rbCXCL8) by immunoprecipitation and Western blotting. SH8- 2A1 could neutralise the chemotactic activity of rbCXCL8 towards neutrophils. The quantitative bCXCL8 ELISA was constituted by the combination of SH8-12A5 and biotin-SH8-2A1. The detection range was 20-1000 pg/mL. A sandwich ELISA was used to measure native bCXCL8 derived from the supernatant of cultured bovine peripheral blood mononuclear cells stimulated with ConA, LPS or PHA. Furthermore, SH8-2A1 More >